Tyme Technologies, Inc. (NASDAQ:TYME) Director Steve Hoffman Sells 78,125 Shares

Tyme Technologies, Inc. (NASDAQ:TYME – Get Rating) Director Steve Hoffman sold 78,125 shares of the stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $0.32, for a total value of $25,000.00. Following the completion of the transaction, the director now directly owns 20,725,691 shares of the company’s stock, valued at approximately $6,632,221.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Steve Hoffman also recently made the following trade(s):

• On Monday, April 11th, Steve Hoffman sold 78,125 shares of Tyme Technologies stock. The stock was sold at an average price of $0.31, for a total value of $24,218.75.
• On Monday, March 28th, Steve Hoffman sold 78,125 shares of Tyme Technologies stock. The shares were sold at an average price of $0.34, for a total value of $26,562.50.
• On Thursday, March 10th, Steve Hoffman sold 78,125 shares of Tyme Technologies stock. The shares were sold at an average price of $0.31, for a total value of $24,218.75.
• On Monday, February 7th, Steve Hoffman sold 78,125 shares of Tyme Technologies stock. The stock was sold at an average price of $0.36, for a total value of $28,125.00.

TYME stock opened at $0.31 on Friday. Tyme Technologies, Inc. has a 52-week low of $0.28 and a 52-week high of $2.02. The business has a 50-day simple moving average of $0.32 and a two-hundred day simple moving average of $0.57. The company has a market capitalization of $53.04 million, a P/E ratio of -2.20 and a beta of 1.08.

Tyme Technologies (NASDAQ:TYME – Get Rating) last released its earnings results on Friday, February 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Large investors have recently bought and sold shares of the stock. Morgan Stanley increased its stake in shares of Tyme Technologies by 382.3% in the first quarter. Morgan Stanley now owns 276,924 shares of the company’s stock worth $493,000 after acquiring an additional 219,507 shares during the period. BlackRock Inc. increased its position in shares of Tyme Technologies by 8.7% during the third quarter. BlackRock Inc. now owns 2,084,696 shares of the company’s stock valued at $2,147,000 after acquiring an additional 166,889 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Tyme Technologies in the third quarter valued at approximately $571,000. Healthcare Value Capital LLC lifted its position in shares of Tyme Technologies by 33.3% during the 3rd quarter. Healthcare Value Capital LLC now owns 2,000,000 shares of the company’s stock worth $2,060,000 after buying an additional 500,000 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in Tyme Technologies in the 4th quarter valued at $109,000. 21.98% of the stock is owned by institutional investors.

Tyme Technologies Company Profile (Get Rating)

Tyme Technologies, Inc, a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.

Further Reading